ObsEva SA
http://www.obseva.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ObsEva SA
Finance Watch: One Small Pain Drug Maker And Three Biotech SPACs Launch IPOs
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
Yselty For Uterine Fibroids Edges Closer To Being Obseva’s First Commercial Product
Positive data from a second Phase III trial will support regulatory filings for linzagolix in the US and Europe, but the GnRH agonist is behind two rival drugs: AbbVie's elagolix and Myovant's relugolix.
Asia Deal Watch: BeiGene Gets Chinese Rights To Two EUSA Rare Disease Therapies
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
ObsEva Gives Up On IVF Drug As Phase III Study Fails
Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a European confirmatory study.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals